Eli Lilly (NYSE:LLY) announced the acquisition of Orna Therapeutics to expand into circular RNA based gene and autoimmune ...
Feb 9 (Reuters) - Eli Lilly will buy therapy developer Orna Therapeutics for up to $2.4 billion in cash, the companies said ...
Diabetic foot ulcers are slow-healing and increase the risk of infections and amputation. Researchers at Karolinska ...
Researchers have gained new insights into largely overlooked circular RNAs in brain cells and the crucial role they play in diseases like Alzheimer’s and Parkinson’s. In addition to providing valuable ...
Eli Lilly (LLY) has agreed to acquire biotechnology company Orna Therapeutics for up to $2.4B in cash, inclusive of an ...
Circular Genomics, a molecular diagnostics company pioneering circular RNA (circRNA)–based biomarkers for neurodegenerative disease, today announced the completion of exclusive intellectual property ...
Eli Lilly (LLY) stock acquiring Orna Therapeutics for up to $2.4 billion to develop circular RNA CAR-T therapies for B ...
A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both a key player in tumor biology and a promising avenue for future therapies.
Eli Lilly (NYSE:LLY) announced an agreement to acquire Orna Therapeutics for up to $2.4b, adding circular RNA and in vivo CAR T technology to its drug development toolkit. The company also expanded ...
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results